Ketesse (Dexketoprofen)

Dexketoprofen works by non‑selectively blocking cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the production of prostaglandins. Lower prostaglandin levels diminish inflammation and decrease the sensitisation of pain receptors, providing both analgesic and anti‑inflammatory effects.

The exact dose of Ketesse is determined by the prescribing clinician based on the individual’s condition, age, renal function and other medications. Healthcare professionals follow local prescribing guidelines to select an appropriate strength and dosing interval for each patient.

Safety data for dexketoprofen in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Ketesse, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ketesse (dexketoprofen) is the active enantiomer of ketoprofen and often provides faster onset of analgesia compared with ibuprofen. Both belong to the NSAID class and share similar mechanisms, but dexketoprofen may require lower doses for comparable pain relief, while the overall safety profile remains comparable, requiring similar gastrointestinal and cardiovascular precautions.

Ketesse should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Ketesse is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may reduce the likelihood of gastrointestinal discomfort. Patients should follow the prescriber’s instructions regarding timing and any specific administration guidelines.

The most serious risks include severe gastrointestinal bleeding, ulceration, renal impairment that may lead to reduced urine output or swelling, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they notice signs of bleeding, sudden kidney problems, or severe allergic symptoms.

Ketesse should be avoided in individuals with known hypersensitivity to dexketoprofen or any other NSAID, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and patients with established cardiovascular disease who are at high risk for thrombotic events unless specifically directed by a physician.